United States
Anji Pharma, established in 2018, is a promising player in the Pharmaceutical industry, headquartered in the United States. The company's slogan, "Bridging science and culture to rapidly bring life-changing therapies to patients in need," encapsulates its mission.
Anji Pharma is strategically focused on high-value targets that have been validated by human genetics, ensuring that its research and clinical endeavors are both exhaustive and agile. The backbone of its success is its team of world-class scientist-entrepreneurs, dedicated to accelerating the availability of innovative medicines on a global scale.
In its relatively short lifespan, Anji Pharma has successfully attracted significant investment interest. Notably, it secured a $70.00M Series B investment on 28 September 2021, with backing from Xiamen Changrong Investment Management. This funding marks a vital endorsement of the company's potential and supports its journey towards transforming the pharmaceutical landscape.
